降钙素原指导疑似或确诊脓毒症患者的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入2004年1月至2016年5月发表的10项英文随机对照试验,共3489例疑似或确诊脓毒症的成人患者,评估降钙素原指导抗生素治疗对疗效与安全性的影响。结果显示,降钙素原指导组抗生素使用时间较对照组缩短(7.35天 vs 8.85天;加权均数差-1.49天;95%CI -2.27至-0.71;p<0.001)。降钙素原指导对死亡率(风险比0.90;95%CI 0.79-1.03;p=0.114)和ICU住院时间(11.09天 vs 11.91天;加权均数差-0.84天;95%CI -2.52至0.84;p=0.329)无不良影响。该研究作为向美国食品药品监督管理局提交监管材料的一部分,旨在为脓毒症成人患者中降钙素原指导的疗效与安全性提供证据汇总。
要点
- 降钙素原指导组抗生素使用时间7.35天 vs 对照组8.85天,加权均数差-1.49天(95%CI -2.27至-0.71;p<0.001)。
- 降钙素原指导对死亡率无不良影响:风险比0.90(95%CI 0.79-1.03;p=0.114)。
- 降钙素原指导对ICU住院时间无不良影响:11.09天 vs 11.91天,加权均数差-0.84天(95%CI -2.52至0.84;p=0.329)。
- 该Meta分析纳入10项随机对照试验、共3489例疑似或确诊脓毒症成人患者,检索PubMed与Cochrane系统评价数据库。
适用人群与场景
- 疑似或确诊脓毒症的成人患者,纳入英文随机对照试验,发表时间为2004年1月至2016年5月。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入10项随机对照试验,共3489例患者;检索PubMed与Cochrane系统评价数据库,采用逆方差加权固定效应与随机效应模型分析。
- 主要疗效终点抗生素使用时间:降钙素原指导组7.35天 vs 对照组8.85天,加权均数差-1.49天(95%CI -2.27至-0.71;p<0.001)。
- 安全性终点全因死亡率:风险比0.90(95%CI 0.79-1.03;p=0.114),降钙素原指导无不良影响。
- 安全性终点ICU住院时间:降钙素原指导组11.09天 vs 对照组11.91天,加权均数差-0.84天(95%CI -2.52至0.84;p=0.329),无不良影响。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,纳入10项随机对照试验;采用Cochrane偏倚风险工具评估偏倚风险;该研究作为向美国食品药品监督管理局提交监管材料的一部分。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在疑似或确诊脓毒症成人患者中,降钙素原指导可缩短抗生素使用时间,且对死亡率与ICU住院时间无不良影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Sepsis is a leading cause of mortality in noncoronary ICUs. Although immediate start of antibiotics reduces sepsis-related mortality, antibiotics are often administered for too long, leading to suboptimal treatment and, importantly, contributes to antimicrobial resistance. Prior literature suggests that procalcitonin correlates with infection and thus may help to guide the decision on when to stop antibiotic treatment. This study was conducted as part of a regulatory submission to the U.S. Food and Drug Administration and aimed to summarize the evidence of procalcitonin guidance on efficacy and safety outcomes in adult patients with sepsis.
DATA SOURCES: PubMed and the Cochrane Database of Systematic Reviews.
STUDY SELECTION: English-language randomized controlled trials evaluating procalcitonin use among adult patients with suspected or confirmed sepsis published between January 2004 and May 2016.
DATA EXTRACTION: Inverse-variance weighting fixed and random effects meta-analyses were performed on the following efficacy and safety endpoints: antibiotic duration, all-cause mortality, and length of ICU stay. Two reviewers independently extracted data elements from identified studies and measured risk of bias with the Cochrane Risk of Bias Tool.
DATA SYNTHESIS: From a total of 369 potentially eligible articles, 10 randomized controlled trials containing 3,489 patients were used for analysis. Procalcitonin-guided patients had shorter antibiotics duration compared with controls (7.35 vs. 8.85 d; weighted mean difference, -1.49 d; 95% CI, -2.27 to -0.71; p < 0.001). Procalcitonin use had no adverse impact on mortality (risk ratio, 0.90; 95% CI, 0.79-1.03; p = 0.114) and length of ICU stay (11.09 d vs. 11.91 d; weighted mean difference, -0.84 d; 95% CI, -2.52 to 0.84; p = 0.329).
CONCLUSIONS: In adult patients with suspected or confirmed sepsis, procalcitonin guidance reduces antibiotics duration with no observed adverse effects on patient outcomes.
参考来源
- Iankova I, Thompson-Leduc P, Kirson NY, et al. Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis. Crit Care Med. 2018. PMID: 29271844. doi:10.1097/CCM.0000000000002928
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。